Genkyotex to Present Updated Interim Results From Phase 2 Trial of GKT831 in Primary Biliary Cholongitis at 2019 EASL International Liver Congress (ILC)
- Interim results selected for oral presentation and inclusion in “Best of ILC” summary
- All patients have completed treatment; favorable safety profile with no drop outs or treatment interruptions due to pruritus
- Final results at week 24 expected in Spring 2019
ARCHAMPS, France, April 08, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today announced that it will present an update on the previously reported interim efficacy results from its Phase 2 trial of GKT831 in Primary Biliary Cholangitis (PBC) during the 2019 EASL International Liver Congress (ILC), being held in Vienna, from April 10-14.
The abstract has been accepted for oral presentation during general session on April 11, from 2:15-2:30 pm. The presentation, entitled “Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial”, was also selected, via a peer-review process, for inclusion in the “Best of ILC” summary slide deck. The results to be presented include the effect of GKT831 on markers of cholestasis and inflammation following just six weeks of treatment.
Elias Papatheodorou, CEO of Genkyotex, commented: “We are pleased by the significant interest KOLs are showing in these data, supporting our differentiated novel therapeutic candidate, GKT831. Unlike other drugs that target primarily cholestasis, GKT831 targets the inflammatory and fibrotic components of PBC. While the antifibrotic activity of GKT831 will be assessed at week 24, GKT831 has already exhibited significant anti-cholestatic and anti-inflammatory activity after only 6 weeks of treatment. GKT831’s mechanism of action has the potential to modify the course of severe diseases in the liver, lungs and the kidneys.”
The Phase 2 trial is a 24-week, double-blind, placebo-controlled study, evaluating the safety and efficacy of GKT831 in patients with PBC following inadequate response to ursodeoxycholic acid (UDCA). A total of 111 PBC patients were enrolled and allocated to three treatment arms: UDCA plus placebo, UDCA plus GKT831 400mg once a day, and UDCA plus GKT831 400mg twice a day. GKT831 has exhibited a particularly favorable safety profile throughout the 24-week treatment period. No drop outs or treatment interruptions due to pruritus or fatigue were reported. Only two serious adverse events were reported, a grade 1 urinary infection and multiple bone fractures related to a traffic accident. Both cases were deemed unrelated to study drug by the investigators. Final results of the trial at week 24 are expected in Spring 2019.
Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets. A leader in NOX therapies, its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.
Genkyotex’s platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes. The lead product candidate, GKT831, a NOX1 and NOX4 inhibitor is evaluated in a phase 2 clinical trial in primary biliary cholangitis (PBC, a fibrotic orphan disease) and in an investigator-initiated Phase 2 clinical trial in Type 1 Diabetes and Kidney Disease (DKD). A grant from the United States National Institutes of Health (NIH) of $8.9 million was awarded to Professor Victor Thannickal at the University of Alabama at Birmingham (UAB) to fund a multi-year research program evaluating the role of NOX enzymes in idiopathic pulmonary fibrosis (IPF), a chronic lung disease that results in fibrosis of the lungs, the core component of the program will be to conduct a Phase 2 trial with the GKT831 in patients with IPF. This product candidate may also be active in other fibrotic indications.
Genkyotex also has a versatile platform well-suited to the development of various immunotherapies (Vaxiclase). A partnership covering the use of Vaxiclase as an antigen per se (GTL003) has been established with Serum Institute of India Private Ltd (Serum Institute), the world’s largest producer of vaccine doses, for the development by Serum Institute of cellular multivalent combination vaccines against a variety of infectious diseases. This partnership could generate approximately €150 million in future revenues for Genkyotex, before royalties on sales.
This press release may contain forward-looking statements by the company with respect to its objectives. Such statements are based upon the current beliefs, estimates and expectations of Genkyotex’s management and are subject to risks and uncertainties such as the company's ability to implement its chosen strategy, customer market trends, changes in technologies and in the company's competitive environment, changes in regulations, clinical or industrial risks and all risks linked to the company's growth. These factors as well as other risks and uncertainties may prevent the company from achieving the objectives outlined in the press release and actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include uncertainties involved in the development of Genkyotex’s products, which may not succeed, or in the delivery of Genkyotex’s products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affect Genkyotex’s capacity to commercialize the products it develops. No guarantee is given on forward-looking statements which are subject to a number of risks, notably those described in the registration document (document de reference) registered by the French Markets Authority (the AMF) on 27 April 2018 under number R.18-037, and those linked to changes in economic conditions, the financial markets, or the markets on which Genkyotex is present. Genkyotex products are currently used for clinical trials only and are not otherwise available for distribution or sale.
|Media relations||Investors relations|
|Sophie Baumont||Brian Ritchie|
|LifeSci Advisors||LifeSci Advisors, LCC|
|+336 2774 74 49||+1-212-915-2578|
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
First Quarter 2019 Results Conference Call24.4.2019 19:55:00 CEST | Pressemelding
AURORA, Ontario, April 24, 2019 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX: MG ) (NYSE: MGA ) FIRST QUARTER 2019 RESULTS CONFERENCE CALL THURSDAY – MAY 9, 2019 8:30 AM ET DIAL IN NUMBERS North America: 1-800-954-0587 International: 1-312-281-2942 Webcast: www.magna.com Slide presentation will be available on our website prior to the call. REBROADCAST INFORMATION Replay available 2 hours after the call until May 16, 2019 North America: 1-800-558-5253 International: 1-416-626-4100 Reservation No.: 21922562 INVESTOR CONTACT Louis Tonelli, Vice-President, Investor Relations firstname.lastname@example.org 905-726-7035 TELECONFERENCE CONTACT Nancy Hansford, Executive Assistant, Investor Relations email@example.com 905-726-7108
Flashpoint Strengthens Intelligence Platform with New Dashboards and Analytics, Expanded Collections and Tailored Alerting by Industry24.4.2019 16:00:00 CEST | Pressemelding
Company Significantly Expands Use-Case Driven Business Risk Intelligence (BRI) Offerings NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Flashpoint, the global leader in Business Risk Intelligence (BRI), today announced new innovations and enhancements that help multiple teams bolster cybersecurity, confront fraud, detect insider threats, enhance corporate and physical security, and address third-party risk. The new innovations and enhancements strengthen Flashpoint Intelligence Platform, which grants access to the company’s archive of finished intelligence reports, data from illicit forums, marketplaces, chat services, paste sites, technical data, card and account shops, and vulnerabilities, in a finished intelligence experience. The platform scales Flashpoint’s internal team of specialized, multilingual intelligence analysts’ ability to quickly provide responses to customers. “As a long-time Flashpoint customer, I have seen many iterations of the company’s platform, technology, and coll
VSBLTY LAUNCHES NEW CORPORATE WEBSITE;SHOWCASES MARKETING & SECURITY TECHNOLOGY24.4.2019 14:05:00 CEST | Pressemelding
Philadelphia, PA, April 24, 2019 (GLOBE NEWSWIRE) -- VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt: 5VS) is pleased to announce the launch of its new, upgraded website (vsblty.net) that demonstrates “The Intersection of Marketing & Security.” VSBLTY is a leading software technology company that provides consumer audience measurement using the power of machine learning through computer vision. Its industry-leading VisionCaptor™ and DataCaptor™ combines motion graphics or interactive brand messaging on any digital display at point of customer contact with “first of its kind” FacialAnalytics. VSBLTY’s measurement technology records demographics such as age, gender, and sentiment as well as audience measurement including content touches, traffic counts, and dwell time. Jay Hutton, VSBLTY Co-Founder and CEO, said, “Our website shows how our digital display solutions are transforming public spaces and providing actionable marketing insights. In addition, VSBLTY Vector™, our disrupt
Fiverr Adds Depth to Management Team, Announces Hila Klein as Chief Operating Officer24.4.2019 14:00:00 CEST | Pressemelding
The veteran executive brings over 15 years of leadership experience to the company as it continues to build upon its mission of changing how the world works together NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Fiverr, a marketplace that connects businesses with freelancers offering digital services, is proud to announce the appointment of Hila Klein as Chief Operating Officer. Klein has a strong background as a product and technology executive, having most recently served as a Senior Vice President, Head of Product Technologies Division at 888 Holdings. She will report directly to Fiverr CEO, Micha Kaufman. “Over the past year, Fiverr has grown both as a business and as an organization. That means the stakes are higher and the challenges are bigger,” said Micha Kaufman, Fiverr CEO. “As such, it was necessary for us to bring in someone to help us oversee all internal processes and procedures. Hila has demonstrated the leadership capabilities that are necessary to help us improve our cr
Qtum Launches Enterprise Blockchain Solution — Unita24.4.2019 10:00:00 CEST | Pressemelding
SHANGHAI, China, April 24, 2019 (GLOBE NEWSWIRE) -- Qtum, the open-source public blockchain platform, launched Unita, a blockchain protocol designed for enterprises. Unita securely stores data, utilizes existing developer tools and automates information transfer processes for businesses at a groundbreaking speed of 10,000 transactions per second. Unita’s flexibility allows a wide population of developers to use common tools to solve the biggest problems businesses face when considering adopting blockchain technology, including consumer data regulations and verification. Unita takes advantage of an innovative, unique, and scalable consensus algorithm, SCAR, that allows parameter adjustments to take place on the blockchain. The dynamic nature of SCAR saves substantial amounts of disk space, bandwidth, and other network resources. Miguel Palencia, Chief Information Officer of the Qtum Foundation, said: “Speed and customization are two of the main barriers for enterprises looking to adopt
Colruyt Group Selects Juniper Networks to Support its Digital Transformation24.4.2019 09:00:00 CEST | Pressemelding
Network Underpins Fast Business Growth for Retail Leader SUNNYVALE, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, today announced that Colruyt Group, one of the largest retailers in Belgium and France, has deployed Juniper Networks’ solutions to improve its data connectivity in response to exponential growth in network traffic. Colruyt Group consists of more than 40 brands for consumers and businesses, including food and non-food retail, fuel, wholesale and food services. Established more than 80 years ago, it operates 553 of its own stores, supplies 581 independent shopkeepers in Belgium and France and also offers its products via e-commerce sites. The group owns the BIO-planet, Collishop, Cru, dreambaby, DreamLand, OKay, SPAR Belgium, MyUnderwear24, NewStory, Newpharma and ZEB brands and operates a network of DATS24 fuel stations throughout Belgium. Colruyt must ensure that it provides quality